Compare IPI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPI | MYGN |
|---|---|---|
| Founded | 2000 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.8M | 444.2M |
| IPO Year | 2007 | 1996 |
| Metric | IPI | MYGN |
|---|---|---|
| Price | $37.75 | $4.16 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $25.00 | $7.64 |
| AVG Volume (30 Days) | 237.7K | ★ 983.9K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.14 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | $298,328,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $5.01 | $6.86 |
| Revenue Next Year | N/A | $5.45 |
| P/E Ratio | $46.99 | ★ N/A |
| Revenue Growth | ★ 17.13 | 2.33 |
| 52 Week Low | $22.55 | $3.76 |
| 52 Week High | $50.34 | $8.59 |
| Indicator | IPI | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 36.06 |
| Support Level | $37.00 | $3.76 |
| Resistance Level | $47.78 | $5.52 |
| Average True Range (ATR) | 1.67 | 0.29 |
| MACD | 0.19 | -0.04 |
| Stochastic Oscillator | 49.55 | 25.32 |
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, where the firm's production facilities are located.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.